drugset

drugset / Trial / NCT05907954

(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma

NCT05907954 ↗

Phase 2 Active not recruiting 160 enrolled IDEAYA Biosciences

NaSingle-groupOpen-labelTreatment

Summary

Neoadjuvant/adjuvant IDE196 (darovasertib) in patients with primary uveal melanoma

Timeline

Start: 2023-07-03
Primary completion: 2027-04-30
Completion: 2030-04-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Darovasertib	Small molecule	—	Oral

Indications